Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

IMPORTANCE: Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic dermatitis (AD). OBJECTIVE: To investigate the efficacy and safety of abrocitinib in adolescents and adults with...

Descripción completa

Detalles Bibliográficos
Autores principales: Silverberg, Jonathan I., Simpson, Eric L., Thyssen, Jacob P., Gooderham, Melinda, Chan, Gary, Feeney, Claire, Biswas, Pinaki, Valdez, Hernan, DiBonaventura, Marco, Nduaka, Chudy, Rojo, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271424/
https://www.ncbi.nlm.nih.gov/pubmed/32492087
http://dx.doi.org/10.1001/jamadermatol.2020.1406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271424/
https://www.ncbi.nlm.nih.gov/pubmed/32492087
http://dx.doi.org/10.1001/jamadermatol.2020.1406

Ejemplares similares